Jaguar Health (JAGX) Lytham Partners Spring 2026 Investor Conference summary

Strategic focus and business development

• Entered a commercial out-license deal for Mytesi and Canalevia-CA1 in early 2026, providing up to $38 million in non-dilutive funding, including $18 million upfront and $20 million in milestones.

• Funds from the deal are being used to advance research and development, particularly in rare disease programs.

• Maintains manufacturing rights for crofelemer, generating additional profit margins.

• Additional funds from supply and inventory purchases were disclosed in recent filings.

Pipeline and clinical development

• Focused on late-stage development for Microvillus Inclusion Disease (MVID), targeting an NDA filing in mid-2027.

• MVID program serves as a stepping stone to short bowel syndrome intestinal failure, a market projected to exceed $8 billion.

• Crofelemer is being developed in a new, highly concentrated liquid formulation for intestinal failure, distinct from the approved Mytesi product.

• Ongoing blinded clinical trial for MVID is fully enrolled with six patients, complemented by expanded access and investigator-initiated cases.

Clinical results and regulatory milestones

• Proof-of-concept data showed crofelemer reduced parenteral support needs by 37% in MVID and 16% in pediatric short bowel syndrome patients.

• Patients experienced improved stool formation and reduced stool volume, indicating better nutrient absorption.

• No safety issues reported in thousands of patients across commercial and clinical use.

• Data will be presented at ESPGHAN in June, with plans to file for Breakthrough Therapy designation with the FDA by year-end.

• NDA filing for MVID is targeted for mid-2027, with short bowel syndrome trial completion expected concurrently.